Cargando…

Surgery for stage IIB–IIIB small cell lung cancer

PURPOSE: The NCCN guidelines do not recommend surgery for T3–4N0M0/T1–4N1–2M0 small cell lung cancer (SCLC) due to a lack of evidence. METHODS: Data of patients with T3–4N0M0/T1–4N1–2M0 SCLC were extracted from the Surveillance, Epidemiology, and End Results (SEER) database to determine the impact o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Zhida, Liu, Yue, Wang, Suyu, Ai, Kaixing, Zhang, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591395/ https://www.ncbi.nlm.nih.gov/pubmed/37872542 http://dx.doi.org/10.1186/s12957-023-03196-2

Ejemplares similares

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
por: Shen, Dijian, et al.
Publicado: (2021)

Clinical outcomes observation in stage IIB–IIIB cervical cancer treated by adjuvant surgery following concurrent chemoradiotherapy
por: Li, Yong, et al.
Publicado: (2021)

Dosimetric comparison of the helical tomotherapy, volumetric-modulated arc therapy and fixed-field intensity-modulated radiotherapy for stage IIB-IIIB non-small cell lung cancer
por: Xu, Yujin, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Chemoradiation and Radiotherapy Treatment for Stage IIB and IIIB Cervical Cancer Patients
por: Puspitasari, Irma M, et al.
Publicado: (2021)

Benefits of surgery in the multimodality treatment of stage IIB-IIIC small cell lung cancer
por: Yang, Yong, et al.
Publicado: (2019)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
por: Xiong, Yicheng, et al.
Publicado: (2023)

Management of type IIB and IIIB olecranon fractures. Case series
por: Ali, Mohammed, et al.
Publicado: (2017)

Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer
por: Liang, Hengrui, et al.
Publicado: (2020)

Ventilation in patients with stage IIIB or above lung cancer
por: Zhang, Haiqin, et al.
Publicado: (2021)

Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer
por: Hughes, Ryan T, et al.
Publicado: (2019)

Glasgow Prognostic Score in Patients Receiving Chemotherapy for Non-small-cell Lung Cancer in Stages IIIb and IV
por: Umihanic, Sefika, et al.
Publicado: (2014)

Robot-assisted thoracic surgery for stages IIB–IVA non-small cell lung cancer: retrospective study of feasibility and outcome
por: Shahin, Ghada M. M., et al.
Publicado: (2023)

A Nomogram to Predict Long-Term Survival Outcomes of Patients Who Undergo Pneumonectomy for Non-small Cell Lung Cancer With Stage I-IIIB
por: Wu, Lei-Lei, et al.
Publicado: (2021)

Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report
por: Tian, Yu, et al.
Publicado: (2020)

Correlations between alterations of T-helper 17 cells and treatment efficacy after concurrent radiochemotherapy in locally advanced cervical cancer (stage IIB–IIIB): a 3-year prospective study
por: Liu, Yi, et al.
Publicado: (2021)

Radiofrequency ablation for stage <IIB non‐small cell lung cancer: Opportunities, challenges, and the road ahead
por: Zhao, Qing, et al.
Publicado: (2023)

Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer
por: Zhao, Lei, et al.
Publicado: (2017)

Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report
por: Zhang, Shuliang, et al.
Publicado: (2022)

Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review
por: Zhou, Nan, et al.
Publicado: (2023)

Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma
por: Koukourakis, M I, et al.
Publicado: (1999)

Prognostic Factors in Stage IIB Non-Small Cell Lung Cancer according to the 8th Edition of TNM Staging System
por: Shin, Jin Won, et al.
Publicado: (2019)

Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancer
por: Gupta, Digant, et al.
Publicado: (2009)

The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy
por: Wang, Yuan, et al.
Publicado: (2017)

Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.
por: Bakker, M., et al.
Publicado: (1995)

Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report
por: Bing, Zhongxing, et al.
Publicado: (2021)

Comparation between novel online models and the AJCC 8th TNM staging system in predicting cancer-specific and overall survival of small cell lung cancer
por: Liu, Meiyun, et al.
Publicado: (2023)

The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma
por: Wang, Ying, et al.
Publicado: (2022)

Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study
por: Ma, Xiaowen, et al.
Publicado: (2015)

Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment
por: Shi, Sheng-Bin, et al.
Publicado: (2013)

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine
por: OZKAYA, SEVKET, et al.
Publicado: (2012)

The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor–Mutated Stage IIIB or IV Non–Small-Cell Lung Cancer Patients
por: Uprety, Dipesh, et al.
Publicado: (2018)

A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer
por: Sun, Manqiang, et al.
Publicado: (2020)

Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study
por: Cheng, Ying, et al.
Publicado: (2018)

Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations
por: Li, Xing, et al.
Publicado: (2019)

Prognostic significance of subclassification of stage IIB lung cancer: a retrospective study of 226 patients
por: Yin, Nanchang, et al.
Publicado: (2017)

A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer
por: Lv, Chao, et al.
Publicado: (2013)

Erratum: Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study
por: Ma, Xiaowen, et al.
Publicado: (2018)

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial
por: Eberhardt, W, et al.
Publicado: (1999)

Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer
por: Fujita, A, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_4bm6p6hs1hp8ljnucqb9ut36g6